These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 32264785)

  • 1. Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer.
    Muir CA; Menzies AM; Clifton-Bligh R; Tsang VHM
    Thyroid; 2020 Oct; 30(10):1458-1469. PubMed ID: 32264785
    [No Abstract]   [Full Text] [Related]  

  • 2. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
    Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Checkpoint Inhibitor-Induced Thyroiditis Is Associated with Increased Intrathyroidal T Lymphocyte Subpopulations.
    Kotwal A; Gustafson MP; Bornschlegl S; Kottschade L; Delivanis DA; Dietz AB; Gandhi M; Ryder M
    Thyroid; 2020 Oct; 30(10):1440-1450. PubMed ID: 32323619
    [No Abstract]   [Full Text] [Related]  

  • 4. Immune Checkpoint Inhibitor-related New-onset Thyroid Dysfunction: A Retrospective Analysis Using the US FDA Adverse Event Reporting System.
    Lu D; Yao J; Yuan G; Gao Y; Zhang J; Guo X
    Oncologist; 2022 Mar; 27(2):e126-e132. PubMed ID: 35641200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct Cytokine Signatures in Thyroiditis Induced by PD-1 or CTLA-4 Blockade: Insights from a New Mouse Model.
    Ippolito S; Di Dalmazi G; Pani F; Sabini E; Caturegli P
    Thyroid; 2021 Dec; 31(12):1839-1849. PubMed ID: 34598661
    [No Abstract]   [Full Text] [Related]  

  • 6. Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer.
    Zhou Y; Xia R; Xiao H; Pu D; Long Y; Ding Z; Liu J; Ma X
    Int Immunopharmacol; 2021 Feb; 91():107296. PubMed ID: 33360368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Combined Effect of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors on Thyroid Function.
    Tsai K; Ma H; Liang TZ; Xing Y; Chung S; Dorff T; Bell D; Lechner MG
    Thyroid; 2024 Feb; 34(2):158-166. PubMed ID: 38069567
    [No Abstract]   [Full Text] [Related]  

  • 8. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
    Kotwal A; Kottschade L; Ryder M
    Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343
    [No Abstract]   [Full Text] [Related]  

  • 9. RAPID EVOLUTION OF THYROID DYSFUNCTION IN PATIENTS TREATED WITH NIVOLUMAB.
    O'Malley G; Lee HJ; Parekh S; Galsky MD; Smith CB; Friedlander P; Yanagisawa RT; Gallagher EJ
    Endocr Pract; 2017 Oct; 23(10):1223-1231. PubMed ID: 29045188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibitor-related thyroid dysfunction.
    Iwama S; Kobayashi T; Yasuda Y; Arima H
    Best Pract Res Clin Endocrinol Metab; 2022 May; 36(3):101660. PubMed ID: 35501263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer.
    Osorio JC; Ni A; Chaft JE; Pollina R; Kasler MK; Stephens D; Rodriguez C; Cambridge L; Rizvi H; Wolchok JD; Merghoub T; Rudin CM; Fish S; Hellmann MD
    Ann Oncol; 2017 Mar; 28(3):583-589. PubMed ID: 27998967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome.
    Kanie K; Iguchi G; Bando H; Urai S; Shichi H; Fujita Y; Matsumoto R; Suda K; Yamamoto M; Fukuoka H; Ogawa W; Takahashi Y
    Cancer Immunol Immunother; 2021 Dec; 70(12):3669-3677. PubMed ID: 33977343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Inhibitor-induced Thyroid Dysfunction Is Associated with Higher Body Mass Index.
    Pollack R; Ashash A; Cahn A; Rottenberg Y; Stern H; Dresner-Pollak R
    J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32668461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyroid Dysfunction in Non-Small Cell Lung Cancer With Immune Checkpoint Inhibitors: A Meta-Analysis.
    Lin L; Yang F; Lin G; Chen X
    J Clin Pharmacol; 2023 Feb; 63(2):210-218. PubMed ID: 36083133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG.
    Knispel S; Stang A; Zimmer L; Lax H; Gutzmer R; Heinzerling L; Weishaupt C; Pföhler C; Gesierich A; Herbst R; Kaehler KC; Weide B; Berking C; Loquai C; Utikal J; Terheyden P; Kaatz M; Schlaak M; Kreuter A; Ulrich J; Mohr P; Dippel E; Livingstone E; Becker JC; Weichenthal M; Chorti E; Gronewold J; Schadendorf D; Ugurel S
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32371460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment.
    Abu-Sbeih H; Tran CN; Ge PS; Bhutani MS; Alasadi M; Naing A; Jazaeri AA; Wang Y
    J Immunother Cancer; 2019 May; 7(1):118. PubMed ID: 31053161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocrine Adverse Events Related To Immune Checkpoint Inhibitor Treatment: Relationship Between Antibodies and Severity of Thyroid Dysfunction.
    González MM; Sanz-Pastor AG; Gómez RÁ; Torrecilla NB; Moreno DM; Fernández LG; Rivas AM; Guerra AL; Álvarez R; Arranz JÁ; Rodas IM; Escudero V; Sanjurjo M; Vallejo JM; Martín M; Albarrán OG
    Endocr Metab Immune Disord Drug Targets; 2024; 24(14):1628-1639. PubMed ID: 38362680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Endocrine side effects of cancer immunotherapy].
    Kroiß M; Schilling B; Deutschbein T
    Dtsch Med Wochenschr; 2020 Dec; 145(24):1736-1741. PubMed ID: 33254246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors.
    Yoon JH; Hong AR; Kim HK; Kang HC
    Endocrinol Metab (Seoul); 2021 Apr; 36(2):413-423. PubMed ID: 33820396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma.
    Morganstein DL; Lai Z; Spain L; Diem S; Levine D; Mace C; Gore M; Larkin J
    Clin Endocrinol (Oxf); 2017 Apr; 86(4):614-620. PubMed ID: 28028828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.